HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 01, January 2018 – Weighing the options       » Scientists close in on origin of SARS       » Chinese researchers map key protein in DNA repair with near-atomic resolution       » Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients       » United States cancer drug costs increasing despite competition       » Eating yogurt may help reduce chronic inflammation in women      
BIOBOARD - OCEANIA
Researcher looks to next generation antibody treatment for chronic kidney disease
A national medical grant has been awarded to fund research into the use of a next generation antibody therapy to treat chronic kidney disease.

Professor Carol Pollock from the University of Sydney has been awarded $768,000 from the National Health and Medical Research Council (NHMRC) to evaluate the drug, AD-114, being developed by the Australian biotech AdAlta.

The project grant, titled “A novel and unique protein i-body for the treatment of Chronic Kidney Disease through targeting CXCR4” will begin on 1 January 2018 and run for four years.

The grant will provide non-dilutive funding to build on the initial work completed by the Kolling Institute and University of Sydney that demonstrated the anti-fibrotic effects of AD-114 in the kidney via a different mechanism of action from currently-approved therapies.

AD-114 has the potential to provide a novel treatment for chronic kidney disease, which currently affects an estimated 1.7 million Australians.

AD-114 differs from existing treatment options and others currently in clinical development as it binds to the chemokine receptor CXCR4. The target CXCR4 is expressed at low levels or absent in healthy tissue and is increased and at high levels in tissue affected by a number of disease states, including fibrosis. AD-114 is the only anti-CXCR4 drug candidate being developed for the treatment of fibrosis.

AdAlta’s CEO, Sam Cobb said: “The research collaboration with the Kolling Institute and University of Sydney has provided the opportunity to expand the AD-114 pre-clinical package; demonstrating anti-fibrotic effects across a range of fibrotic diseases, which will be important to potential pharmaceutical partners.

We are looking forward to further developing AD-114 for Chronic Kidney Disease, providing an additional clinical application which further enhances the value of AD-114.”

Professor Carol Pollock added, “An increase in diabetes and obesity across the world is leading to a massive surge in the number of people diagnosed with CKD. The medical community is looking for alternate treatment options to treat CKD, highlighting the importance of research funding to evaluate new clinical targets. We are excited by the opportunity to further evaluate CXCR4’s involvement and this novel i-body for the treatment of Chronic Kidney Disease”.

Click here for the complete issue.

NEWS CRUNCH  
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Addressing the ageing population / Clinical trials
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy